A6951658
Cabergoline , 10mMinDMSO , 81409-90-7
Synonym(s):
Cabergoline;Dostinex;Cabaser;1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea;1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea
CAS NO.：81409-90-7
Empirical Formula: C26H37N5O2
Molecular Weight: 451.6
MDL number: MFCD00867887
EINECS: 200-419-0
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB559.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 102-104°C |
| Density | 1.156±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO: ≥10mg/mL |
| form | powder |
| pka | 13.05±0.46(Predicted) |
| color | White to Off-White |
| optical activity | [α]/D 61 to 68°, c = 0.5 in dichloromethane |
| Stability: | Hygroscopic |
| InChIKey | KORNTPPJEAJQIU-KJXAQDMKSA-N |
| SMILES | [C@]12([H])C[C@H](CN(CC=C)[C@]1([H])CC1=CNC3C=CC=C2C1=3)C(=O)N(CCCN(C)C)C(=O)NCC |&1:0,3,9,r| |
Description and Uses
Cabergoline is a potent, selective, and long-lasting dopamine D2 receptor agonist launched in 1993 in Belgium as a prolactin inhibitor. A single 1 mg dose of cabergoline effectively prevents puerperal lactation for up to 14 days, remarkably superior to other drugs that require a daily regimen. It has a low rate of rebound breast activity and good tolerability. Cabergoline is also in clinical trials for Parkinson's disease, breast cancer, and hyperprolactinaemia.
receptor stimulant
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P264-P270-P301+P312-P302+P352-P305+P351+P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36/37 |
| WGK Germany | 3 |
| RTECS | KE6167600 |
| HS Code | 2939690000 |
| Toxicity | Sol in ethyl alcohol, chloroform, DMF; slightly sol in 0.1 N HCl; very slightly sol in n-hexane. Insol in water. LD50 orally in male mice: >400 mg/kg (Brambilla) |
